Dergiler / Journal of Basic and Clinical Health Sciences / 2021 / Cilt: 5 - Sayı: 1
EVALUATION OF THE FACTORS AFFECTING THE LENGTH OF STAY IN HOSPITAL OF TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) CASES
- Sayfa
- 22–29
- DOI
- —
Abstract
Purpose: In the treatment of inoperable patients with severe aortic stenosis or at high surgical risk,transcatheter aortic valve implantation (TAVI) is applied as an alternative to surgical aortic valvereplacement. In our study, it was aimed to evaluate the factors affecting the length of stay in hospital ofTAVI cases.Method: After obtaining the approval of the ethics committee, the patients who received TAVI between09.06.2012-19.01.2018 in the Interventional Cardiology unit of Dokuz Eylül University were retrospectivelyscreened. A total of 243 patients were included in the study. Demographic data, preoperativeaccompanying diseases and echocardiographic results of the cases, the type of anesthesia applied, theduration of postoperative coronary intensive care and hospital stay of them were recorded. The analysisof the data was carried out in the SPSS 22.0 statistical package program, and the independent variablesand their relationship with discharge were tested with chi-square analysis.Results: 53.5% of the patients who underwent transcatheter aortic valve implantation received generalanesthesia, 46.5% received local anesthesia and sedation. 93.8% of the patients were discharged uponrecovery. There was no significant difference between patients' gender, age, mitral insufficiency level,aortic insufficiency level, tricuspid insufficiency level, aortic valve area, and preoperative comorbiddiseases and postoperative discharge time (p> 0.05). There was a significant difference between thepostoperative length of stay in hospital and the type of anesthesia (p=0.008). It was shown that patientsunderwent general anesthesia were discharged later than patients underwent sedation.Conclusion: Due to the high risks of surgery, it is of vital importance to shorten the length of stay inhospital in high-risk patients over 65 years of age who undergo TAVI.